TTR and primary systemic amyloidosis: Translation of the p5+14 peptide as a clinical imaging agent for patients with AL and transthyretin-associated systemic amyloidosis is currently being supported by the Science Moving towArds Research Translation and Therapy (SMARTT) Program at the National Heart, Lung and Blood Institute of the NIH.